EPL Ltd Q4 FY2022 Concall Summary

Source transcript PDF: https://www.stockscans.in/document/mapxpu8fl8l171hbhhklakc8.pdf

Key Takeaways


Pricing & Margin Dynamics

Kripalu: "Last time we said that our margins are bottomed out and then the Ukraine war happened right and there was a concomitant set... I have to caveat this by saying that the environment just remains unbelievably unpredictable."

Regional & Category Performance

Region / CategoryTrendCommentary
MSR (Middle East, South Asia, Africa)▲ StrongRevenue grew 23.4% for the full year, the fastest of all regions.
Americas▲ StrongFull-year revenue up 12.9%; personal care delivered double-digit growth in beauty, cosmetics, and pharma combined. Q4 exit margin improved to 15.7% vs the full-year average.
EAP (East Asia Pacific)▲ SolidFull-year revenue grew 10.3%.
Europe▼ WeakFull-year revenue declined 2.6% but grew 4.7% excluding Russia and hand sanitizer; Q4 grew 4.2% (7.3% adjusted). Personal care category shrank through the entire COVID wave, but management is optimistic about a bounce-back.
China (within EAP)▼ Sharp QoQ declineQ4 hit by Chinese New Year impact worse than usual, huge input cost increases, and COVID starting to materially impact toward quarter-end. All operations remained running.
Oral Care▲ SteadyGrew 8% in Q4, 10.2% for the full year.
Personal Care▲ Faster than OralGrew 9.5% in Q4, 11.2% for the full year, despite significant COVID impact on the category in Europe. Sustained at 46% of revenue mix.

China Uncertainty

Kripalu: "We have a sense that the worst maybe behind us right as far as March and April is concerned but in this game I would hasten to caveat that by saying we do not know for sure..."

Strategic Initiatives & Sustainability


Management’s Stance on Disclosure


Guidance & Commitments

CommitmentSpecificsTimeline
Platina volume rampVolumes to grow exponentially across large and small customersFY2023
Cost containmentActions across every P&L line: in-house caps, scrap reduction, org efficiencyOngoing
Pricing model shiftMove from periodic to monthly price conversations with customersAlready underway
Brazil revenue contributionMaterial impact expectedFY2024 (nominal in FY2023)
Inventory normalizationReduce inventories from elevated levels once conditions normalizeNo date (conditions-dependent)
Long-term margin recoveryMargins to return to prior levels or better when commodity prices temperNo date (commodity cycle-dependent)

Key Metrics

MetricQ4 FY22
Revenue growth8.6%, 9.4% adjusted for Russia in the base
Oral care growth8%
Personal care growth9.5%
EBITDA margin15.4%, lower than 15.7% in Q3 FY22
Europe revenue growth4.2%, 7.3% adjusted excluding Russia and hand sanitizer
Europe EBITDA margin11.9%
Americas EBITDA margin15.7%
FY22 revenue growth11%, 11.2% like-for-like excluding Russia, CSPL and hand sanitizer
FY22 oral care growth10.2%
FY22 personal care growth11.2%
FY22 MSR region growth23.4%
FY22 EAP region growth10.3%
FY22 Americas region growth12.9%
FY22 Europe revenue growth-2.6%, 4.7% adjusted excluding Russia and hand sanitizer
FY22 EBITDA margin16.8%, a decline of 306 bps versus FY21
FY22 net profit decline16%, net of one-offs PAT down 12.3% versus previous year
Gross margin~50%
Personal care revenue mix46% of composition, sustained over last three to four quarters
China revenue share~25% of topline
Creative acquisition investment₹168 cr, from internal accruals